Biomarkers of ADHD Treatment Response
Launched by BOSTON CHILDREN'S HOSPITAL · Dec 6, 2022
Trial Information
Current as of February 05, 2025
Completed
Keywords
ClinConnect Summary
This clinical trial, called "Biomarkers of ADHD Treatment Response," is studying how brain activity can help predict how well children with ADHD will respond to two common medications: Concerta (methylphenidate) and Adderall (mixed amphetamine salts). The researchers want to find out if children who improve with Concerta have different brain patterns compared to those who don’t respond well. They will also look to see if children do better on Adderall have distinct brain signatures when compared to their responses to Concerta.
To participate, children aged 7 to 11 who have been diagnosed with ADHD and have not yet tried stimulant medications may be eligible. During the study, children will have their brain activity measured before starting either medication and again after a three-week trial period. Families will also share information each week about the child's symptoms and any side effects they may experience. This study will help provide a better understanding of how to tailor ADHD treatments based on individual responses, making it easier for doctors to find the right medication for each child.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Pediatric patients ages 7-11 seen at the Children's Hospital Primary Care Center
- • Have a diagnosis of ADHD or referred for an ADHD evaluation
- • Have not previously trialed stimulant medication
- Exclusion Criteria:
- • Diagnoses of intellectual disability, autism, prior suicide attempt, current psychotropic medication use, known genetic syndrome, color-blindness
- • History of nonfebrile seizures
- • Gestational age \< 32 weeks
- • Prenatal alcohol or substance exposure
- • Medical conditions that contraindicate psychostimulant use (e.g., cardiac concerns).
Trial Officials
Anne B Arnett, PhD
Principal Investigator
Boston Children's Hospital
Eugenia Chan, MD
Principal Investigator
Boston Children's Hospital
About Boston Children's Hospital
Boston Children's Hospital is a leading pediatric healthcare institution renowned for its commitment to advancing child health through innovative research and exceptional clinical care. As a prominent clinical trial sponsor, the hospital leverages its extensive expertise in pediatric medicine to conduct rigorous and ethically sound research studies aimed at improving treatment options and outcomes for children. With a collaborative approach that integrates cutting-edge technology and multidisciplinary teams, Boston Children's Hospital is dedicated to translating scientific discoveries into practical applications that enhance the well-being of young patients and their families.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Brookline, Massachusetts, United States
People applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Discussion 0
Similar Trials